Emirates consensus recommendations on cardiovascular risk management in type 2 diabetes
BackgroundThe combination of cardiovascular disease and diabetes is a highly prevalent condition in the United Arab Emirates. Development and dissemination of evidence-based regional recommendations for optimal screening, treatment and referrals of people with diabetes and high cardiovascular risk i...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2024.1395630/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841558833177034752 |
|---|---|
| author | Hani Sabbour Hani Sabbour Hani Sabbour Wael Almahmeed Wael Almahmeed Fatheya Alawadi Fatheya Alawadi Abdullah Shehab Abdulamjeed Al Zubaidi Alaaeldin Bashier Abdul Rauf Ghulam Fauzia Rashid Hosam Zaky Hussien Heshmat Kassemn Hussien Heshmat Kassemn Jamila Bin Adi Juwairia Tahir Khadija Hafidh Mohammed Farghali Mohamed Hassanien Mohamed Hassanien James Januzzi |
| author_facet | Hani Sabbour Hani Sabbour Hani Sabbour Wael Almahmeed Wael Almahmeed Fatheya Alawadi Fatheya Alawadi Abdullah Shehab Abdulamjeed Al Zubaidi Alaaeldin Bashier Abdul Rauf Ghulam Fauzia Rashid Hosam Zaky Hussien Heshmat Kassemn Hussien Heshmat Kassemn Jamila Bin Adi Juwairia Tahir Khadija Hafidh Mohammed Farghali Mohamed Hassanien Mohamed Hassanien James Januzzi |
| author_sort | Hani Sabbour |
| collection | DOAJ |
| description | BackgroundThe combination of cardiovascular disease and diabetes is a highly prevalent condition in the United Arab Emirates. Development and dissemination of evidence-based regional recommendations for optimal screening, treatment and referrals of people with diabetes and high cardiovascular risk is an important priority.Consensus panelAn expert panel of diabetologists, endocrinologists and cardiologists from the Emirates Cardiac Society and Emirates Diabetes and Endocrine Society as well as different entities in the UAE, discussed and reviewed evidence and also a consensus report from the American Diabetes Association to formulate contextualized recommendations that could be applied for optimal management of cardiovascular risk in people with diabetes in the UAE.Consensus findingsThe combination of heart failure and other cardiovascular risks is a highly prevalent finding among people with diabetes in the United Arab Emirates. The causal inter-relationships between diabetes and heart failure are multifactorial and regular assessments of symptoms and steps for mitigation of risk factors are an important priority. The universal definition and classification of heart failure provides a useful framework for recommending optimal screening, treatment, and referral strategies to diabetic individuals at various stages of the cardiovascular continuum. Routine measurement (at least yearly) of natriuretic peptides and high-sensitivity troponins can help identify patients requiring cardiac imaging referrals. However, recommending routine measurements of natriuretic peptides and/or high-sensitivity troponins to all diabetic individuals must balance clinical judgment and cost implications. While SGLT2i must be an important part of the standard of care, insulin, GLP1 receptor agonists and/or metformin can be useful for additional glycemic control.ConclusionThe consensus panel hopes that the recommendations presented herein can offer guidance for optimal screening, treatment and referral of people with a concomitance of diabetes and high cardiovascular risk in the United Arab Emirates. |
| format | Article |
| id | doaj-art-51475d0fcd6b4bdc92b175fcd8a8911d |
| institution | Kabale University |
| issn | 1664-2392 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj-art-51475d0fcd6b4bdc92b175fcd8a8911d2025-01-06T04:13:52ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922025-01-011510.3389/fendo.2024.13956301395630Emirates consensus recommendations on cardiovascular risk management in type 2 diabetesHani Sabbour0Hani Sabbour1Hani Sabbour2Wael Almahmeed3Wael Almahmeed4Fatheya Alawadi5Fatheya Alawadi6Abdullah Shehab7Abdulamjeed Al Zubaidi8Alaaeldin Bashier9Abdul Rauf Ghulam10Fauzia Rashid11Hosam Zaky12Hussien Heshmat Kassemn13Hussien Heshmat Kassemn14Jamila Bin Adi15Juwairia Tahir16Khadija Hafidh17Mohammed Farghali18Mohamed Hassanien19Mohamed Hassanien20James Januzzi21Mediclinic Hospital, Abu Dhabi, United Arab EmiratesImperial College London Diabetes Center, Abu Dhabi, United Arab EmiratesWarren Alpert School of Medicine, Brown University, Providence, RI, United StatesCardiology, Cleveland Clinic, Abu Dhabi, United Arab EmiratesHeart, Vascular and Thoracic Institute, Cleveland Clinic, Abu Dhabi, United Arab EmiratesEndocrine Section, Dubai Hospital, Dubai Academic Health Corporation (DAHC), Dubai, United Arab EmiratesCollege of Medicine, Mohammed Bin Rashid University of Medicine and Health Science (MBRU), Dubai, United Arab EmiratesCardiology Division, Mediclinic Hospitals, Al Ain, United Arab EmiratesBurjeel Hospital, Abu Dhabi, United Arab EmiratesEndocrine Section, Dubai Hospital, Dubai Academic Health Corporation (DAHC), Dubai, United Arab Emirates0Benefits Design and Strategic Purchasing Department, Healthcare, Abu Dhabi, United Arab Emirates1Dubai Hospital, Dubai, United Arab Emirates2Cardiology Department, Dubai Hospital, Dubai Academic Health Corporation (DAHC), Dubai, United Arab Emirates3Cardiology Department, Zulekha Hospitals, Dubai, United Arab Emirates4Cardiology Department, Cairo University, Cairo, Egypt5The Emirates Society of Internal Medicine, Internal Medicine Rashid Hospital, Dubai Health Authority, Dubai, United Arab Emirates6The Emirates Cardiac Society, Rashid Hospital, Dubai, United Arab Emirates7Internal Medicine Department, Rashid Hospital, Dubai Academic Health Corporation (DAHC), Dubai, United Arab Emirates8Medical Department, Dubai Medical College, Dubai, United Arab EmiratesEndocrine Section, Dubai Hospital, Dubai Academic Health Corporation (DAHC), Dubai, United Arab EmiratesCollege of Medicine, Mohammed Bin Rashid University of Medicine and Health Science (MBRU), Dubai, United Arab Emirates9Massachusetts General Hospital, Harvard Medical School, Boston, MA, United StatesBackgroundThe combination of cardiovascular disease and diabetes is a highly prevalent condition in the United Arab Emirates. Development and dissemination of evidence-based regional recommendations for optimal screening, treatment and referrals of people with diabetes and high cardiovascular risk is an important priority.Consensus panelAn expert panel of diabetologists, endocrinologists and cardiologists from the Emirates Cardiac Society and Emirates Diabetes and Endocrine Society as well as different entities in the UAE, discussed and reviewed evidence and also a consensus report from the American Diabetes Association to formulate contextualized recommendations that could be applied for optimal management of cardiovascular risk in people with diabetes in the UAE.Consensus findingsThe combination of heart failure and other cardiovascular risks is a highly prevalent finding among people with diabetes in the United Arab Emirates. The causal inter-relationships between diabetes and heart failure are multifactorial and regular assessments of symptoms and steps for mitigation of risk factors are an important priority. The universal definition and classification of heart failure provides a useful framework for recommending optimal screening, treatment, and referral strategies to diabetic individuals at various stages of the cardiovascular continuum. Routine measurement (at least yearly) of natriuretic peptides and high-sensitivity troponins can help identify patients requiring cardiac imaging referrals. However, recommending routine measurements of natriuretic peptides and/or high-sensitivity troponins to all diabetic individuals must balance clinical judgment and cost implications. While SGLT2i must be an important part of the standard of care, insulin, GLP1 receptor agonists and/or metformin can be useful for additional glycemic control.ConclusionThe consensus panel hopes that the recommendations presented herein can offer guidance for optimal screening, treatment and referral of people with a concomitance of diabetes and high cardiovascular risk in the United Arab Emirates.https://www.frontiersin.org/articles/10.3389/fendo.2024.1395630/fulldiabetesheart failurecardiovascular risksbiomarkersUAE |
| spellingShingle | Hani Sabbour Hani Sabbour Hani Sabbour Wael Almahmeed Wael Almahmeed Fatheya Alawadi Fatheya Alawadi Abdullah Shehab Abdulamjeed Al Zubaidi Alaaeldin Bashier Abdul Rauf Ghulam Fauzia Rashid Hosam Zaky Hussien Heshmat Kassemn Hussien Heshmat Kassemn Jamila Bin Adi Juwairia Tahir Khadija Hafidh Mohammed Farghali Mohamed Hassanien Mohamed Hassanien James Januzzi Emirates consensus recommendations on cardiovascular risk management in type 2 diabetes Frontiers in Endocrinology diabetes heart failure cardiovascular risks biomarkers UAE |
| title | Emirates consensus recommendations on cardiovascular risk management in type 2 diabetes |
| title_full | Emirates consensus recommendations on cardiovascular risk management in type 2 diabetes |
| title_fullStr | Emirates consensus recommendations on cardiovascular risk management in type 2 diabetes |
| title_full_unstemmed | Emirates consensus recommendations on cardiovascular risk management in type 2 diabetes |
| title_short | Emirates consensus recommendations on cardiovascular risk management in type 2 diabetes |
| title_sort | emirates consensus recommendations on cardiovascular risk management in type 2 diabetes |
| topic | diabetes heart failure cardiovascular risks biomarkers UAE |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2024.1395630/full |
| work_keys_str_mv | AT hanisabbour emiratesconsensusrecommendationsoncardiovascularriskmanagementintype2diabetes AT hanisabbour emiratesconsensusrecommendationsoncardiovascularriskmanagementintype2diabetes AT hanisabbour emiratesconsensusrecommendationsoncardiovascularriskmanagementintype2diabetes AT waelalmahmeed emiratesconsensusrecommendationsoncardiovascularriskmanagementintype2diabetes AT waelalmahmeed emiratesconsensusrecommendationsoncardiovascularriskmanagementintype2diabetes AT fatheyaalawadi emiratesconsensusrecommendationsoncardiovascularriskmanagementintype2diabetes AT fatheyaalawadi emiratesconsensusrecommendationsoncardiovascularriskmanagementintype2diabetes AT abdullahshehab emiratesconsensusrecommendationsoncardiovascularriskmanagementintype2diabetes AT abdulamjeedalzubaidi emiratesconsensusrecommendationsoncardiovascularriskmanagementintype2diabetes AT alaaeldinbashier emiratesconsensusrecommendationsoncardiovascularriskmanagementintype2diabetes AT abdulraufghulam emiratesconsensusrecommendationsoncardiovascularriskmanagementintype2diabetes AT fauziarashid emiratesconsensusrecommendationsoncardiovascularriskmanagementintype2diabetes AT hosamzaky emiratesconsensusrecommendationsoncardiovascularriskmanagementintype2diabetes AT hussienheshmatkassemn emiratesconsensusrecommendationsoncardiovascularriskmanagementintype2diabetes AT hussienheshmatkassemn emiratesconsensusrecommendationsoncardiovascularriskmanagementintype2diabetes AT jamilabinadi emiratesconsensusrecommendationsoncardiovascularriskmanagementintype2diabetes AT juwairiatahir emiratesconsensusrecommendationsoncardiovascularriskmanagementintype2diabetes AT khadijahafidh emiratesconsensusrecommendationsoncardiovascularriskmanagementintype2diabetes AT mohammedfarghali emiratesconsensusrecommendationsoncardiovascularriskmanagementintype2diabetes AT mohamedhassanien emiratesconsensusrecommendationsoncardiovascularriskmanagementintype2diabetes AT mohamedhassanien emiratesconsensusrecommendationsoncardiovascularriskmanagementintype2diabetes AT jamesjanuzzi emiratesconsensusrecommendationsoncardiovascularriskmanagementintype2diabetes |